An experimental drug called daraxonrasib has nearly doubled survival time for patients with advanced pancreatic cancer in clinical trials, marking a significant breakthrough against one of the world’s deadliest malignancies.
Results presented at the American Society of Clinical Oncology annual meeting in June showed that daraxonrasib improved median overall survival from 6.7 months with standard chemotherapy to 13.2 months. The drug reduced the overall risk of death by 60 percent compared to chemotherapy.
The trial enrolled 500 patients with metastatic pancreatic cancer who had already received prior treatment. Revolution Medicines, the company developing the drug, presented these results on May 31 and published them in the New England Journal of Medicine.
What makes daraxonrasib different is its mechanism. The drug specifically targets the RAS signaling pathway, a critical pathway controlling cancer cell growth and progression. For decades, scientists considered RAS an “undruggable” target — a protein that seemed impossible to disable with medication. Daraxonrasib proves that’s no longer true.
Pancreatic cancer is among the most aggressive cancers. Most patients are diagnosed when the disease is already advanced. Five-year survival rates remain below 15 percent. Any drug that meaningfully extends survival represents progress in a disease where progress has been rare.
The FDA has already granted daraxonrasib Breakthrough Therapy and Orphan Drug designations, fast-tracking regulatory review. The drug is available now through expanded access treatment protocols, allowing pancreatic cancer patients who have already undergone chemotherapy to receive it.
The drug’s availability matters. Rather than waiting months or years for full FDA approval, terminally ill patients can access it immediately under compassionate use policies. This reflects the standard in oncology: dying patients shouldn’t wait for paperwork when a potentially life-extending therapy exists.
